Trial reportMedicine2025
The effect of Jing Si herbal tea on cancer-related fatigue in gynecologic cancer patients: A randomized controlled trial.
Trial report in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer-related fatigue (CRF) is a persistent, distressing, subjective sense of physical, emotional, or cognitive tiredness or exhaustion disproportionate to recent activity and interferes with normal functioning. Jing Si herbal tea (JSHT) has shown several pharmacological actions in preclinical and clinical models. We aimed to investigate the effect of JSHT on alleviating CRF in patients with gynecological cancer.
methodsA randomized controlled trial was conducted at our hospital from March 1, 2021 to December 31, 2023. Participants aged 20 to 80 years with gynecologic cancer and moderate-to-severe CRF were randomly categorized into 2 groups. The intervention group was given JSHT twice daily for 6 weeks, while the control group was given a placebo for 3 weeks and JSHT for the following 3 weeks. The primary outcomes were fatigue and quality of life, which were evaluated using the brief fatigue inventory-total (BFI-T) and functional assessment of cancer therapy-general 7 scale. The secondary outcomes included white blood cells and differential counts.
resultsAmong the 19 participants, there was no significant difference in CRF (BFI-T) and quality of life (functional assessment of cancer therapy-general 7) improvement between the intervention group (n = 9) and the control group (n = 10). However, both groups showed significant improvements in BFI-T: global fatigue score, BFI-T: fatigue intensity, and BFI-T: fatigue interference after treatment (P < .05). The difference in monocyte count was statistically significant after treatment in both groups (P < .001), with the intervention group showing a significant decrease in monocyte count compared to the control group at the beginning of cycle 2 (P < .05).
conclusionBoth intervention and control groups improved fatigue and decreased monocyte counts. Further research is needed to explore these findings and their clinical relevance.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.